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Introduction: Previous magnetic resonance spectroscopy (MRS) and mass spectroscopy studies have shown
accumulation of 2-hydroxyglutarate (2HG) in mutant isocitrate dehydrogenase (IDH) gliomas. IDH mutation is known
to be a powerful positive prognostic marker in malignant gliomas. Hence, 2HG accumulation in gliomas was assumed
to be a positive prognostic factor in gliomas, but this has not yet been proven. Here, we analyzed 52 patients harboring
World Health Organization (WHO) grade II and III gliomas utilizing 3.0-tesla MRS.
Results: Mutant IDH gliomas showed significantly higher accumulation of 2HG (median 5.077 vs. 0.000, p =0.0002,
Mann–Whitney test). 2HG was detectable in all mutant IDH gliomas, whereas in 10 out of 27 (37.0%) wild-type IDH
gliomas, 2HG was below the detectable range (2HG =0) (p =0.0003, chi-squared test). Screening for IDH mutation by
2HG analysis was highly sensitive (cutoff 2HG =1.489 mM, sensitivity 100.0%, specificity 72.2%). Gliomas with high 2HG
accumulation had better overall survival than gliomas with low 2HG accumulation (p =0.0401, Kaplan-Meier analysis).
Discussion: 2HG accumulation detected by 3.0-tesla MRS not only correlates well with IDH status, but also positively
correlates with survival in WHO grade II and III gliomas.
Keywords: Glioma, MRS, 2-hydroxyglutarate, IDH mutation, Prognostic markerIntroduction
A comprehensive genomic analysis of glioblastomas has
shown that mutations of isocitrate dehydrogenase (IDH)
are found in a subset of glioblastoma [1], and subse-
quent studies have found IDH mutation to be a powerful
prognostic factor in malignant gliomas [2], suggesting
that IDH mutations represent a clinically distinct subset
of gliomas. The accumulation of 2-hydroxyglutarate (2HG)
is noted in the cytoplasm of glioma cells with IDH1 muta-
tion and in the mitochondria of cells with IDH2 mutation
(Figure 1) [3]. Magnetic resonance spectroscopy (MRS)
[4-10] as well as mass spectrometry [3,10-12] are known to
effectively measure 2HG in glioma tissues with good corre-
lations to IDH mutation status. 2HG is an oncometabolite,* Correspondence: higara@bri.niigata-u.ac.jp
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article, unless otherwise stated.which has been shown to cause tumorigenesis by inhibition
of histone demethylation [13-15] and DNA demethylation
[16,15]. 2HG accumulation in gliomas was assumed to
positively correlate with patient survival because of the
correlation of IDH status to patient survival in malignant
gliomas. However, to date, this has not been proven. In the
present study, 2HG accumulation was shown to have a
positive correlation with overall patient survival in WHO
grade II and III gliomas for the first time.Materials and methods
Participants
Seventy-one adult patients harboring World Health
Organization (WHO) grade II or III gliomas, receiving
magnetic resonance spectroscopy (MRS) evaluation at
the Center for Integrated Brain Science, University of
Niigata, before surgery and surgical treatment at the
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Figure 1 Schematic representation of 2HG production in IDH mutant gliomas. Accumulation of 2HG is seen in the cytoplasm of mutant
IDH1 and mitochondria of mutant IDH2 gliomas. 2HG is also derived from glutamine in mutant IDH gliomas.
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study. Patients with non-astrocytic, non-oligodendroglial,
and non-oligoastrocytic tumors (e.g. ependymomas, n =11),
patients whose MRS scans had low signal-to-noise ratios
(S/N) of less than 4 (n =4), patients having a glioblastoma-
like single voxel MRS (SVMRS) spectra at relapse reflecting
radiation necrosis or malignant transformation (n =2), a
patient harboring a cystic lesion with insufficient volume
of a solid component (n =1), and a patient lost to follow
up (n =1), were excluded from the analysis. Thus, a total
of 52 patients were ultimately analyzed. Written informed
consent was obtained from all of the participants in
accordance with the human research guidelines of the
Internal Review Board of University of Niigata.
MRS analysis
MRI/1H-MRS was performed using a 3.0-tesla system
(Signa LX, General Electric, Waukesha, WI) with an 8
channel phased array coil head. First, proton density
images (Fast Spin Echo; TR/TE =5000/40; FOV: 20 ×
20 mm; matrix: 256 × 256; slice thickness: 5 mm; inter
slice gap: 2.5 mm) were taken. The slice with the largest
depiction of tumor on proton density images was selected
for SVMRS. A point-resolved spectroscopic sequence
(PRESS), with chemical-shift-selective water suppression
was used with the following parameters: (TR: 1.5 s; TE:
30 ms; data point 512; spectral width 1000Hz; number of
acquisitions: 128–196; volume of interest (VOI): 12–20 ×
12–20 × 12–20 mm).
Spectral analysis was performed using LCModel ver-
sion 6.3 (Stephen Provencher, Oakville, Ontario, Canada)
[17]. This software automatically adjusts the phase and
chemical shift of the spectra, estimates the baseline, and
performs eddy current corrections. Relative metabolite
concentrations and their uncertainties were estimated byfitting the spectrum to a basis set of spectra acquired
from individual metabolites in solution. The basis set was
made with MR experiment simulation software (GAMMA,
Radiology, Duke University Medical Center, Durham, NC)
and provided by Dr.Steven Provencher [17] and was cali-
brated with MRS phantom solution (18-cm-diameter MRS
HDsphere, model 2152220; General Electric, Milwaukee,
WI) using our MR system. Nineteen metabolites were
included in this LCModel basis set: alanine, aspartate,
creatine (Cr), phosphocreatine (PCr), γ- aminobutyric acid,
glucose, glutamine (Gln), glutamate (Glu), glycerophospho-
choline (GPC), phosphocholine (PC), gluthathione (GSH),
2-hydroxyglutarate (2HG), myo-inositol (Ins), lactate, NAA
(N-acetylaspartate), N-acetylaspartylglutamate (NAAG),
scyllo-inositol, taurine, and guanine. Total NAA (tNAA:
the sum of NAA and NAAG), total choline (tCho: the
sum of GPC and PC), total creatine (tCr: the sum of Cr
and PCr), and sum of Glu and Gln (Glx) were noted. To
calculate the absolute metabolite concentrations, an un-
suppressed water signal was used as a reference.
Quantification estimates of metabolites were consid-
ered unreliable and excluded when Cramer-Rao lower
bounds, returned as the percentage of standard deviation
(%SD) by LCModel, was greater than 35%, as previously
described [18]. Because low 2HG and GSH estimates
yielded large %SDs (i.e. when 2HG =0, %SD =∞), the
above exclusion criteria was applied only when the esti-
mated 2HG amount was greater than 1.0 mM or GSH
was greater than 0.5 mM. Glx and tNAA were excluded
when %SD was greater than 30%; tCho and tCr were
excluded when %SD was greater than 20%.
Pathological analysis and IDH analysis
Surgical specimens were analyzed by two pathologists
(H.T. and A.K.) and diagnosed according to the WHO
Table 1 Patient characteristics of mutant and wild-type
IDH groups
Characteristic Number of patients (%) p value
Mutant IDH Wild-type IDH
Number 25 27
Men: Women 14:11 14:13
Age (years)
Median 45 61 0.0008*
Range 26-67 28-77
Newly diagnosed 22 (88.0) 25 (92.6) 0.9279
Recurrent 3 (12.0) 2 (7.4)
Pathological grade
WHO Grade II 17 (68.0) 7 (25.9) 0.0024*
WHO Grade III 8 (32.0) 20 (74.1)
Outcome
Alive 20 (80.0) 12 (44.4) 0.0085*
Dead 5 (20.0) 15 (55.6)
Results of unpaired t-test (age) and chi-squared tests (others). The values
inside parentheses represent percentage of patients within each group.
*p <0.05.
IDH: isocitrate dehydrogenase; WHO: World Health Organization.
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(IHC) analysis (H09 clone, Dianova, Hamburg, Germany;
1:100) was performed in formalin-fixed, paraffin imbedded
section using the avidin-biotin-peroxide method (Vector,
Burlingame, CA, USA) with diaminobenzidine as the
chromogen and counterstained with hematoxylin.
For cases showing negative staining for IDH1 R132H,
DNA sequencing for IDH1 and IDH2 was analyzed.
Genomic DNA was extracted from paraffin-embedded
sections, and as described previously [20,21], PCR ampli-
fication was performed by using primer sets (forward: 5’-
CGGTCTTCAGAGAAGCCATT-3’, and reverse 5’-TT
CATACCTTGCTTAATGGGTGT-3’) at codon 132 for
the IDH1 gene and (forward: 5’-AATTTTAGGACCCC
CGTCTG-3’, and reverse 5’-CTGCAGAGACAAGAGG
ATGG-3’) at codon 172 for the IDH2 gene. The PCR
products were then sequenced on a 3130xl Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA)
with a Big Dye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems) in accordance with the manufac-
turer’s instructions.
Statistical analysis
Corrected metabolite concentrations of patients harboring
mutant IDH gliomas were compared to those harboring
gliomas of wild-type IDH using the Mann–Whitney U test.
Receiver operating characteristic (ROC) curve was used to
determine a cutoff for 2HG concentration to obtain max-
imal sensitivity and specificity to identify IDH mutations.
Kaplan-Meier analysis was used to compare overall sur-
vival. Tests for associations between different parameters
were carried out by the chi-squared test for 2 × 2 contin-
gency tables. p <0.05 was considered significant. Statistical
analyses were performed using GraphPad Prism 6 software
(GraphPad Software, http://www.graphpad.com).
Results
A summary of the patient characteristics of mutant and
wild-type IDH groups is provided in Table 1. Median pa-
tient age was 53 years; Patients harboring mutant IDH
gliomas were younger than those with wild-type IDH gli-
omas (45 years vs. 61 years, p =0.0008, Mann–Whitney
U test). A majority (90.4%) of the patients analyzed were
newly-diagnosed patients. IDH mutations were found in
only 25 out of 52 cases (48.1%), this was probably due
to: the inclusion of primary glioblastoma and glioblastoma
with oligodendroglioma component, failure to detect rare
IDH1 and IDH2 mutations by DNA sequencing, and/or
selection bias due to the preoperative availability of MRS.
There were more WHO grade II tumors (68.0% vs. 25.9%,
p =0.0024) and more patients were alive at last follow-up
in the mutant IDH group (80.0% vs. 44.4%, p =0.0085).
Representative SVMRS spectra of mutant IDH and
wild-type IDH gliomas are provided in Figure 2. Smallpeaks were detected at a chemical shift of about 2.25 ppm
in mutant IDH gliomas. Both spectra have similar choline
peaks, but these were not adjusted for choline.
Mutant IDH gliomas showed a significantly higher
accumulation of 2HG (median 5.077 mM vs. 0.000 mM,
p =0.0002, Mann–Whitney test). Mutant IDH gliomas
also showed lower levels of GSH (median 1.849 vs. 2.409,
p =0.0328) and Glx (median 7.701 vs. 9.528, p =0.001)
compared to the wild-type IDH gliomas (Figure 3A). Levels
of Ins, tNAA, tCho, and tCr were not significantly different
between the two groups.
ROC curve analysis obtained a cutoff of 2HG =1.489 mM,
with a sensitivity of 100.0% and specificity of 72.2%, to
detect IDH mutations (Figure 3B). 2HG was detectable
in all mutant IDH gliomas, whereas in 10 out of 27
(37.0%) wild-type IDH gliomas, 2HG was not detectable
(2HG =0) (p =0.0003). Five (18.5%) of the wild-type
IDH gliomas had an accumulation of 2HG higher than
1.489 mM; three gliomas (11.1%) yielded a concentra-
tion of 2HG higher than 5 mM (Figure 3B). A signi-
ficantly longer overall patient survival was noted in
gliomas with high accumulation of 2HG (p =0.0401,
Figure 4). Median survival was 823 days in glioma
patients with low 2HG; median patient survival was not
reached in the glioma patients with high 2HG. There
was no significant difference in survival between pa-
tients harboring wild-type IDH glioma patients with
high 2HG accumulation (2HG >1.489 mM) vs. low 2HG
accumulation (p =0.4894, Kaplan-Meier curves not
shown). Likewise there was no significant difference in
survival between mutant IDH gliomas with high 2HG
Figure 2 SVMRS spectra of mutant IDH and wild-type IDH gliomas. Representative SVMRS spectra of mutant IDH (red) and wild-type IDH
gliomas (blue) are shown. Small peaks were detected at a chemical shift of about 2.25 ppm in mutant IDH gliomas. Both spectra have similar
choline peaks, but these were not adjusted for choline.
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tion (p =0.8815, Additional file 1: Figure S1), although
median survival has not been reached in either group.
Discussion
IDH1 and IDH2 enzymes catalyze oxidative decarboxyl-
ation of isocitrate to α-ketoglutarate (α-KG). Mutant IDH
cannot catalyze this reaction and instead reduces α-KG to
2HG [3] (Figure 1). 2HG is oxidized by 2-hydroxyglutarate
dehydrogenase (2-HGDH) back to α-KG, and the muta-
tion of 2-HGDH is known to cause 2-hydroxyglutaric
aciduria [22]. A previous study has shown that glutamate
is the main source of carbons for 2HG in mutant IDH
glioma cells [3].
In our study, 2HG was detected in all mutant IDH
gliomas. On the other hand, in a subset of wild-type IDH
gliomas, a high 2HG concentration was noted (Figure 3B).
This may be attributed to false-positive results [23] or a
failure to detect rare IDH1 or IDH2 mutations by DNAFigure 3 2HG is accumulated in mutant IDH gliomas. A) Comparisons
show markedly higher accumulation of 2-HG (median 5.007 mM vs. 0.000 m
(p <0.05) in mutant IDH gliomas. B) ROC curve analysis revealed an optima
2HG was detectable in all mutant IDH gliomas, whereas in 10 out of 27 (37.0%
chi-squared test). Five out of 27 (10.3%) wild-type IDH gliomas yielded a 2-HGsequencing. However, a recent study showed millimolar
concentrations of 2HG in wild-type IDH breast cancer
tissues. These accumulations were found to be associated
with MYC, and carry a poor prognosis [24]. It remains to
be seen if mechanisms of 2HG accumulation unrelated to
IDH mutation exist in gliomas as well.
It is known that 2HG is primarily derived from glu-
tamine in mutant IDH gliomas. Glutamine is hydrolyzed
by glutaminase to produce glutamate, which is subse-
quently converted to α-KG [3,25]. MYC is known to
regulate glutamine utilization and glutaminase protein ex-
pression [26], and mutant IDH gliomas are known to have
an increased expression of MYC [27]. Interestingly, we
found less accumulation of Glx (Glu +Gln) in the mutant
IDH gliomas (p <0.005, Figure 3), suggesting that glutam-
ine consumption is contributing to the accumulation of
α-KG and ultimately 2HG (Figure 1) in these tumors.
2HG acts as a competitive antagonist of α-KG, causing
inhibition of α-KG-dependent dioxygenases. These includeof amount of metabolites in mutant IDH and wild-type IDH gliomas
M, Mann–Whitney test, p =0.0002) and lower concentrations of Glx
l cutoff of 1.489, with a sensitivity of 100.0% and specificity of 72.2%.
) wild-type IDH gliomas, 2HG was not detectable (2HG =0) (p =0.0003,
concentration higher than 1.489 mM.
Figure 4 Longer overall survival in high 2HG glioma patients.
The overall survival was significantly longer in glioma patients with
high accumulation of 2HG (2HG >1.489) compared with low
accumulation (p =0.401, Kaplan-Meier analysis).
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which cause histone demethylation [13-15], and the ten-
eleven translocation (TET) family of DNA hydroxylases,
which cause DNA demethylation [16,15]. This was consist-
ent with data from the The Cancer Genome Atlas (TCGA)
database, in which the proneural subgroup of glioblastoma
was found to be enriched with IDH mutations and display
hypermethylation in a large number of loci [28]. A recent
report has shown the stimulation of HIF prolyl hydroxy-
lases by (R) enantiomer of 2HG in mutant IDH immortal-
ized astrocytes leads to a reduced level of HIF, but
enhanced proliferation [29].
There are still others who hypothesize that mutant
IDH is not tumorigenic, but actually makes tumor cells
susceptible to death, evidenced by the longer survival of
patients with IDH mutant glioma patients [30]. Mutant
IDH1 and 2HG were shown to induce oxidative stress,
cell-killing autophagy and apoptosis in a cell type spe-
cific manner [31]. New evidence suggests that IDH1
mutation inhibits the growth of glioma cells via GSH in-
hibition and generation of reactive oxygen species (ROS)
[32]. This study, as well as previous MRS [10] and meta-
bolomic [11] studies have shown that GSH is depleted in
mutant IDH gliomas.
At least 8 different mutations of IDH1 and IDH2 are
known in gliomas, at the IDH1 R132 and IDH2 R172
loci. 2HG can be detected in gliomas in vitro by mass-
spectrometry or in vivo by MRS. One of the proposed
advantages of detecting 2HG is that it would provide a
screening for all mutations of IDH1 and IDH2, as all
IDH mutations that are known to produce 2HG [33].
The 2HG molecule contains five nonexchangeable
protons, giving rise to multiplets at three locations on 3 T
MRS: approximately 4.02, 2.25, and 1.90 ppm (Figure 2)
[5]. The multiplet at 2.25 ppm is larger than the other
2HG multiplets. The detection of this multiplet is compli-
cated by the spectral overlap of Glu (2.43 ppm), Gln(2.34 ppm), and GABA (2.28 ppm) [34]. Direct detection
of the multiplet at 1.90 ppm is difficult due to its proxim-
ity to NAA resonance at 2.01 ppm. Finally, the multiplet
at 4.02 is partially overlapped with Cr (3.92 ppm), PCr
(3.94 ppm), Ins (4.06 ppm), lactate (4.1 ppm) and free Cho
(4.05 ppm) [5].
A false-positive rate of approximately 22% was
observed by Pope et al. using the short-echo MRS with
TE at 30 ms for the detection of 2HG [10]. This false-
positive rate can be reduced by using long-echo MRS
with TE at 97 ms with the use of three-dimensional
volume-localized basis (VLB) spectra, which has been
shown to be optimal for detection of 2HG [5,6]. A com-
parative study of PRESS sequences at short- (35 ms) and
long- TE (97 ms) found long- TE to be superior for the
following reasons: 1) it permits a more favorable voxel
localization, and 2) it produces a well-defined narrow
2HG signal at 2.25 ppm, thereby leading to improved
differentiation between 2HG and Glu, Gln, and GABA
signals. Spectral fitting of PRESS data at TE =97 ms was
effective in minimizing the effect of macromolecule sig-
nals [5]. Five (18.5%) wild-type IDH gliomas in this study
were found to have high 2HG accumulation of more
than 1.489 mM. Further analysis of these specimens by
either mass spectrometry or ex vivo MRS is needed to
determine whether these results could be attributed to
false positive readouts.
Unambiguous detection of 2HG in mutant IDH glioma
was achieved by 2D correlation spectroscopy (COSY)
[4,7,8] and J-difference spectroscopy [4]. However, these
methods are less available clinically and involve longer
acquisition time; 2D correlation MRS involves complex
quantification and has less sensitivity [23]. We achieved
100% sensitivity of 2HG detection by short-echo MRS
with modulation of 2HG resonances by spectral fitting.
Less acquisition time enabled glioma patients, even those
with relatively poor performance status, to undergo ana-
lysis. The biggest advantage of detecting 2HG by MRS is
that it provides an opportunity for pre-surgical, non-
invasive detection of 2HG, thus reliably predicting IDH
status of gliomas before surgery. There is increasing inter-
est that mutant IDH patients may benefit from extensive
surgery [35,36]. Also, 2HG is known to degrade after
formalin fixation and paraffin embedding [12]. Ex vivo
assessment of 2HG by MRS or mass spectrometry enable
the analysis of homogeneous tumor tissue, but sample
degradation and the necessity for treating tissues with
reagents pose problems [23].
2HG detection by in vivo MRS may be utilized to
evaluate response to glioma treatments. IDH mutations
are known to be very tumor-cell-specific [37], and 2HG
accumulation is found to be increased in tumor tissues
compared to surrounding tissue. This leads to the notion
that 2HG will not be assessable after surgical removal of
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logically known to be very infiltrative tumors, with indi-
vidual glioma cells extending deep into adjacent brain
tissues [38]. If 2HG can be detected in adjacent brain
tissues by MRS, gliomas can be evaluated serially even
after surgical removal of a majority of the tumor. Other
metabolites such as Cho, Gln, Glu, lactate, NAA and Cr
can be detected in conjunction with 2HG, and this meta-
bolic profile may be utilized to characterize tumor aggres-
siveness after chemotherapy and radiotherapy, at relapse
and may even predict outcome [39].
Potent inhibitors of mutant IDH1 have been developed
and are implicated in clinical trials in the United States.
In vitro studies analyzing 2HG have shown a reduction
of 2HG after usage of these inhibitors [40-42]. 2HG ana-
lysis by MRS would be an appropriate method to deter-
mine biological response of this drug in glioma patients.
Conclusions
Increasing evidence suggests that 2HG is an important
oncometabolite in mutant IDH gliomas. In vivo MRS
has been shown to effectively measure 2HG and predict
IDH status preoperatively in WHO grade II and grade
III glioma patients. We found 2HG to be a positive
prognostic factor in these gliomas. Further studies are
warranted for other possible mechanisms of 2HG accu-
mulation in gliomas.
Additional file
Additional file 1: No survival difference between mutant IDH
glioma patients with high vs. low 2HG accumulation. No difference
in survival between mutant IDH glioma patients with high 2HG
accumulation (2HG >5.077 mM) vs. low 2HG accumulation was noted
(p =0.8815). Median survival has not been reached in either group.
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